ArticleJournal of experimental & clinical cancer research : CR2011
RNAi-mediated knockdown of cyclooxygenase2 inhibits the growth, invasion and migration of SaOS2 human osteosarcoma cells: a case control study.
Article in Journal of experimental & clinical cancer research : CR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Landscape of the immune infiltration and identification of molecular diagnostic markers associated with immune cells in patients with kidney transplantation.Scientific reports · 2024Article
- Immunotherapy of osteosarcoma based on immune microenvironment modulation.Frontiers in immunology · 2024Review
- Identification of Biomarkers for Predicting Allograft Rejection following Kidney Transplantation Based on the Weighted Gene Coexpression Network Analysis.BioMed research international · 2021Article
- KRAB domain of ZFP568 disrupts TRIM28-mediated abnormal interactions in cancer cells.NAR cancer · 2020Article
- Effect of Ultrafine Powderization and Solid Dispersion Formation via Hot-Melt Extrusion on Antioxidant, Anti-Inflammatory, and the Human Kv1.3 Channel Inhibitory Activities ofBioinorganic chemistry and applications · 2020Article
- Reversine induces caspase-dependent apoptosis of human osteosarcoma cells through extrinsic and intrinsic apoptotic signaling pathways.Genes & genomics · 2019Article
- Knockdown of cyclooxygenase-2 leads to growth inhibition and cell cycle arrest in hepatocellular carcinoma cells.OncoTargets and therapy · 2019Article
- Identification of key gene modules for human osteosarcoma by co-expression analysis.World journal of surgical oncology · 2018Article
- Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor.Neoplasia (New York, N.Y.) · 2017Article
- P50-associated COX-2 extragenic RNA (PACER) overexpression promotes proliferation and metastasis of osteosarcoma cells by activating COX-2 gene.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Depletion of ALX1 causes inhibition of migration and induction of apoptosis in human osteosarcoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- RUNX2 RNA interference inhibits the invasion of osteosarcoma.Oncology letters · 2015Article
- Cyclooxygeanse-2 promotes metastasis in osteosarcoma.Cancer cell international · 2015Article
- Analysis of gene expression in cyclooxygenase-2-overexpressed human osteosarcoma cell lines.Genomics & informatics · 2014Article
- Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors.Translational oncology · 2014Article
- Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.British journal of cancer · 2014Article
- Prostaglandin E(2) in tick saliva regulates macrophage cell migration and cytokine profile.Parasites & vectors · 2013Article
- Resolution of PMA-induced skin inflammation involves interaction of IFN-γ and ALOX15.Mediators of inflammation · 2013Article
- The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyclooxygenase2 (COX-2), one isoform of cyclooxygenase proinflammatory enzymes, is responsible for tumor development, invasion and metastasis. Due to its role and frequent overexpression in a variety of human malignancies, including osteosarcoma, COX-2 has received considerable attention. However, the function of COX-2 in the pathogenesis of cancer is not well understood. We examined the role of COX-2 in osteosarcoma.
methodsWe employed lentivirus mediated-RNA interference technology to knockdown endogenous gene COX-2 expression in human osteosarcoma cells (SaOS2) and analyzed the phenotypical changes. The effect of COX-2 treatment on the proliferation, cell cycle, invasion and migration of the SaOS2 cells were assessed using the MTT, flow cytometry, invasion and migration assays, respectively. COX-2, vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF) mRNA and protein expression were detected by RT-PCR and western blotting.
resultsOur results indicate that a decrease of COX-2 expression in human osteosarcoma cells significantly inhibited the growth, decreased the invasion and migration ability of SaOS2 cells. In addition, it also reduced VEGF, EGF and bFGF mRNA and protein expression.
conclusionsThe COX-2 signaling pathway may provide a novel therapeutic target for the treatment of human osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.